Biofrontera Inc. (BFRI)
BFRI moved a median of -0.90% 30 minutes after news, and -2.08% by the close. How BFRI actually reacts to news — the realized, point-in-time move the market made, measured across 244 labeled events over the last three years with zero look-ahead.
BFRI’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 30% | 226 |
| 30-min | -0.90% | 37% | 237 |
| 60-min | -0.94% | 33% | 240 |
| to close | -2.08% | 32% | 239 |
| Middle 50% of BFRI reactions | -2.80% to +1.26% |
|---|---|
| Median reaction (30-min) | -0.90% |
| Measured reactions | 244 |
Half of all Biofrontera Inc. news events land between -2.80% and +1.26% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when BFRI moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to BFRI's baseline. Nothing else.
Recent BFRI events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body | Press release | GlobeNewswire | -2.19% | -1.78% | |
| Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma | Press release | GlobeNewswire | -5.26% | -10.53% | |
| Form 8-K Biofrontera Inc. For: Sep 14 | SEC filing · Form 8-K | SEC EDGAR | -1.31% | -8.69% | |
| Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth | Press release | GlobeNewswire | +1.57% | -0.79% | |
| Form 10-Q Biofrontera Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +1.56% | |
| Form 8-K Biofrontera Inc. For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +1.57% | -0.79% | |
| Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026 | Press release | GlobeNewswire | -0.01% | +0.00% | |
| Form 10-K/A Biofrontera Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | +1.87% | |
| Form S-8 Biofrontera Inc. | SEC filing · Form S-8 | SEC EDGAR | +0.00% | +1.87% | |
| Form 8-K Biofrontera Inc. For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.71% | |
| Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 | Press release | GlobeNewswire | -0.59% | -4.94% | |
| Biofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update | Press release | GlobeNewswire | +4.54% | +12.34% | |
| Form 10-Q Biofrontera Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +2.10% | -15.79% | |
| Form 8-K Biofrontera Inc. For: May 14 | SEC filing · Form 8-K | SEC EDGAR | +4.54% | +12.34% | |
| Biofrontera Launches Second Annual “Hats On” Campaign to Raise Awareness of Actinic Keratosis | Press release | GlobeNewswire | -1.03% | -1.05% | |
| Biofrontera Inc. to Report First Quarter 2026 Financial Results and Host a Conference Call on May 14, 2026 | Press release | GlobeNewswire | -1.27% | -5.93% | |
| Form DEF 14A Biofrontera Inc. For: Apr 30 | SEC filing · Form DEF | SEC EDGAR | -1.82% | -1.82% | |
| Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update | Press release | GlobeNewswire | -2.08% | -2.77% | |
| Form 10-K Biofrontera Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.47% | +0.69% | |
| Form 8-K Biofrontera Inc. For: Mar 19 | SEC filing · Form 8-K | SEC EDGAR | +5.30% | -2.05% | |
| Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris | Press release | GlobeNewswire | -4.04% | -4.74% | |
| Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026 | Press release | GlobeNewswire | -1.82% | +1.22% | |
| Form 8-K Biofrontera Inc. For: Mar 09 | SEC filing · Form 8-K | SEC EDGAR | -4.04% | -4.74% | |
| Form 8-K Biofrontera Inc. For: Feb 23 | SEC filing · Form 8-K | SEC EDGAR | +0.89% | +2.98% | |
| U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma’s Patent 11,697,028 To Be Unpatentable | Press release | GlobeNewswire | +0.89% | +2.98% | |
| Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities | Press release | GlobeNewswire | -1.82% | +7.93% | |
| Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma | Press release | GlobeNewswire | -1.44% | -7.46% | |
| Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint | Press release | GlobeNewswire | -19.87% | -11.06% | |
| Form 8-K Biofrontera Inc. For: Feb 09 | SEC filing · Form 8-K | SEC EDGAR | -19.87% | -11.06% | |
| Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year Growth | Press release | GlobeNewswire | -7.59% | -8.75% | |
| Form 8-K Biofrontera Inc. For: Jan 13 | SEC filing · Form 8-K | SEC EDGAR | -7.59% | -8.75% | |
| Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory Milestones | Press release | GlobeNewswire | -1.00% | +3.12% | |
| Form 8-K Biofrontera Inc. For: Dec 31 | SEC filing · Form 8-K | SEC EDGAR | -1.00% | +3.12% | |
| Form EFFECT Biofrontera Inc. | SEC filing · Form EFFECT | SEC EDGAR | — | -1.82% | |
| Biofrontera Inc. Completes Transfer of Ameluz® and RhodoLED® FDA approval and Associated Intellectual Property Portfolio | Press release | GlobeNewswire | +1.64% | -3.12% | |
| Form S-1 Biofrontera Inc. | SEC filing · Form S-1 | SEC EDGAR | -2.19% | +0.40% | |
| Last Patient Completes Biofrontera’s Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities | Press release | GlobeNewswire | -1.92% | +2.84% | |
| Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT | Press release | GlobeNewswire | -0.17% | -1.40% | |
| Biofrontera Inc. Reports Third Quarter 2025 Financial Results and Provides a Business Update | Press release | GlobeNewswire | -2.46% | — | |
| Form 8-K Biofrontera Inc. For: Nov 13 | SEC filing · Form 8-K | SEC EDGAR | -2.46% | — | |
| Form 10-Q Biofrontera Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.46% | — | |
| Form 8-K Biofrontera Inc. For: Nov 04 | SEC filing · Form 8-K | SEC EDGAR | +1.98% | +2.97% | |
| Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M | Press release | GlobeNewswire | +0.89% | -4.42% | |
| Form 8-K Biofrontera Inc. For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | +0.89% | -4.42% | |
| Biofrontera Inc. to Report Third Quarter 2025 Financial Results on November 12, 2025 and Host a Conference Call on November 13, 2025 | Press release | GlobeNewswire | +0.89% | -4.42% | |
| Form 8-K Biofrontera Inc. For: Oct 20 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -10.09% | |
| Biofrontera Inc. Closes Purchase of All Ameluz® and RhodoLED® US Assets from Biofrontera AG | Press release | GlobeNewswire | -1.98% | +13.00% | |
| Form 8-K Biofrontera Inc. For: Oct 23 | SEC filing · Form 8-K | SEC EDGAR | -1.98% | +13.00% | |
| Biofrontera Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025 | Press release | GlobeNewswire | +0.00% | -0.01% | |
| Biofrontera Inc. Engages Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication Program | Press release | GlobeNewswire | -10.78% | -6.66% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the BFRI section they belong to.
Where else BFRI is measured.
BFRI earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Biofrontera Inc.'s median reaction calculated?
Every labeled BFRI news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 244 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 37% of BFRI's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does BFRI's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.